Refine by
Fluorescence Imaging Articles & Analysis: Older
16 news found
CD Bioparticles now offers multiple particles with different fluorescence intensities and particle sizes for encoding. These particles with different surface functionalizations can be used in standard flow cytometry or fluorescence-based imaging platforms. ...
This cutting-edge imaging technique offers enhanced resolution and imaging capabilities, allowing researchers to visualize biological samples with unprecedented detail. ...
CD Bioparticles also provides PLGA nanoparticles covalently linked to streptavidin proteins on the surface for a variety of applications, such as dual-labeled fluorescent and magnetic nanoparticles for in vivo targeting. For example, DiagPoly™ Streptavidin Coated Fluorescent Magnetic PLGA Nanoparticles, DiO, 120 nm (Cat.No. CDPLN-01) are labeled with DiO as ...
Quantum points have revealed great potential in analytical applications, but their emission wavelengths in the visible region limit their application, especially in fluorescence imaging for medical diagnostics. Given this, researchers often systematically tune quantum dots to emit different wavelengths, from the visible to the near-infrared region, by adjusting ...
OnLume Inc., a Madison, Wisconsin-based medical imaging company with unique technology for improving surgical precision in the operating room, has announced the start of participation in a clinical trial combining its fluorescence-guided surgery (FGS) imaging device with a novel nerve-targeting agent. ...
National Institutes of Health (NIH)’s National Cancer Institute (NCI) to advance development of its proprietary device for Fluorescence-Guided Surgery (FGS). OnLume has developed novel FGS imaging technology to illuminate critical anatomy in real-time during surgery to optimize precision, which can lead to improved patient outcomes, reduced morbidity and ...
Food & Drug Administration (“FDA”) to market its first product, a fluorescence guided surgery (FGS) system. The OnLume Imaging System is indicated for fluorescence imaging of blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, reconstructive, and micro ...
Belonging to the carbon family, GQDs have outstanding performance owing to their ultra-small size, non-toxicity, biocompatibility, excellent photo stability, tunable fluorescence, and water solubility, and thus captures considerable attention in the energy and biomedical fields. “In general, GQDs can be used in the manufacturing of many products such as batteries, ...
(“Avelas” or “the Company”), a clinical-stage drug-device company pioneering the field of fluorescence imaging for real-time cancer detection, announces today additions to its senior management team and Board of Directors and provides an update on the pegloprastide Phase III clinical program, due to start in 1H22. ...
OnLume Surgical, a Wisconsin-based medical device company developing novel imaging systems for use during surgery, announced the completion of its Series A funding to assist its plans for commercial launch. ...
SAN DIEGO, CA – Avelas Biosciences, Inc., pioneering the field of intraoperative fluorescent cancer imaging, today announced that the company has received Breakthrough Therapy designation from the U.S. ...
The 2020 Wisconsin Innovation Awards Winners: OnLume Surgical Onlume Madison OnLume provides real time, surgical fluorescence imaging of blood flow, cancer and nerves. Madison Pinpoint Software helps the grocery and healthcare industry prevent expired inventory and improve operational consistency. ...
In addition, optimal dosing and imaging conditions, including fluorescent thresholds, to achieve differentiation between malignant and nonmalignant tissue in margin-relevant tissue was determined. ...
AVB-620 has completed a Phase Ib clinical trial assessing safety, pharmacokinetics, and fluorescence properties using tissue image analysis. A Phase II clinical trial for AVB-620 in breast cancer is ongoing. ...
OnLume Inc., a medical device company developing novel surgical imaging technology, was accepted into the SBIR Advance program sponsored by the Center for Technology Commercialization (CTC). ...
OnLume Inc., a medical device company developing novel surgical imaging technology, today announced support from the Small Business Innovation Research (SBIR) program to accelerate work on a fluorescence image-guided surgery (FIGS) system. OnLume received the $300,000 Phase I SBIR grant through the National Cancer Institute (NCI) at the National ...